Slide 1: PIOLAX, INC. (Code: 5988)
Wednesday, June 4, 2025 PIOLAX, INC. (Code: 5988) Satoshi Yamada, President All Rights Reserved, Copyright © PIOLAX, INC. 1
Slide 2: Shift in Management Policy
Shift in Management Policy Piolax has grown in line with the increasing car production • Introduced business unit system by product line (fasteners, fuel system parts, powertrain parts, open and close mechanism parts). • Pursued management rationality by focusing on the four product lines. Changes i
Slide 3: Shift in Management Policy
Shift in Management Policy ◼ Product Strategy Capture changing market needs as CASE grows and create new high- value-added products utilizing our existing technologies. • Target items: ADAS-related parts, bus bars, electric unit parts *See pages 6-7 ◼ Regional Strategy Determine key regions/items/cu
Slide 4: Medium- to Long-Term Sales Plan
Medium- to Long-Term Sales Plan * Numbers in parentheses are those announced in the “notice regarding the revision of the medium-term management plan" on February 12, 2025. (¥100 mil.) FY24 results FY25 FY26 FY27 FY30 Sales 633 (630) 620 660 690 850 Operating profit 23 (29) 21 46 63 90 Operating pro
Slide 5: Sales Expansion Activity
Sales Expansion Activity ・Increase per-car sales for major OEMs. ■ Sales and ratio by OEM ・Enhance the customer portfolio by (¥100 mil.) strengthening sales to non-Japanese OEMs. 800 582 622 600 ■ Per-car sales 14% 17% Non-JPN OEMs (JPY/Car) Major JPN OEMs (Japan) (JPY/Car) Major Non-JPN OEMs 400 49
Slide 6: Product Strategy
Product Strategy ■ Application and evolution of our conventional technology Leveraging our accumulated know-how in metals and resins, we will focus on products that meet market needs for lighter weight, quietness, and environmental friendliness with the spread of electric and hybrid vehicles. Latche
Slide 7: Product Strategy: CASE compatible products
Product Strategy ■CASE compatible products We take the changing product needs with the spread of CASE as business opportunities. Our sales of CASE products are increasing steadily. We will concentrate our resources on major items to achieve sales of 10 billion yen in FY30. Electric Latches Damping s
Slide 8: Regional Strategy
Regional Strategy China North America Increase sales to Chinese OEMs Increase sales to Big 3 FY30: Sales of ¥11 bil. of more FY30: Sales of ¥18 bil. or more (¥4 bil. to Chinese OEMs) 1) Review business structure (sales, development). 1) Build a system so that all processes from design and 2) Conside
Slide 9: All Rights Reserved, Copyright © PIOLAX, INC.
All Rights Reserved, Copyright © PIOLAX, INC. 9
Slide 10: Business Strategy -1
Business Strategy -1 ■Sales and operating profit ratio of medical device business (PIOLAX MEDICAL DEVICES, INC.) (¥100 mil.) 120 15% Sales Operating profit ratio(Right axis) 100 100 10% 80 68 10% 58 60 49 51 6% 52 6% 40 5% 3% 20 1% -2% 0 0% Plan Results Plan Plan Plan Target 2024 2025 2026 2027 ・・・
Slide 11: Business Strategy -2
Business Strategy -2 Define product lines to focus on: medical devices for minimally invasive treatment Market launch plan Product lines and sales targets in 2030 2025 2026 2027 2028-2030 2 products Stents 2 Products (Biodegradable stent) New) ¥1.2 bil. (Cancer treatment) (Cancer treatment) Guidewir
Slide 12: Product to Focus on (New Product)
Product to Focus on (New Product) ■ Japan's first biodegradable gastrointestinal stent (esophagus) receiving regulatory approval Stent body Target group Patients with benign esophageal stricture who frequently undergo balloon dilatation Effect Reduce the risk of stenosis recurrence and the number of
Slide 13: All Rights Reserved, Copyright © PIOLAX, INC.
All Rights Reserved, Copyright © PIOLAX, INC. 13
Slide 14: Capital Policy Update
Capital Policy Update Based on the disclosure on November 7, 2024 and tender offer for own shares (TBO) implemented from February 13, 2025, our capital policy is as follows. No. Item Details From November 8, 2024, we acquired treasury shares worth ¥24.3 billion in total (¥2.6 billion via market purc
Slide 15: For Appropriate Capital Adequacy Ratio
For Appropriate Capital Adequacy Ratio March 2024 May 2025 Target Liabilities ¥13.5 bi. 1) 4) Cash, deposits Cash, deposits Cash, deposits Liabilities ¥15.0 bil. ¥35.7 bil. ¥34.9 bil. ¥35.5 bil. 2) Liabilities ¥40.0 bil. Equity 5) Other assets Other assets (incl. ¥107.9 bil. Other assets (incl. fixe
Slide 16: All Rights Reserved, Copyright © PIOLAX, INC.
All Rights Reserved, Copyright © PIOLAX, INC. 16
Slide 17: Sustainability Initiatives
Sustainability Initiatives Carbon neutrality (CN): -46% in FY30 (from FY19) Diversity FY23: Introduced 100% renewable energy at the Moka and Fuji FY24 FY30 Target Plants and Piolax Medical Devices. Ratio of female managers 6.3% 20% or more FY24: Included overseas subsidiaries in our roadmap. Gender
Slide 18: Precaution for Handling This Document
Precaution for Handling This Document The forward-looking statements regarding our company in this document are based on information currently available to us. Please note that they are only projections at this time containing risks and uncertainties, and actual results may differ significantly from